SIRT1 and chronic kidney disease: It has been reported that the impaired de novo pathway, including the altered tryptophan metabolism, is involved in decreased NAD+ levels in CKD, and the uremic toxin indoxyl sulfate was shown to reduce the contents of Sirt1 and Sirt3 in the CKD rat model [198,199,200].